Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Intravesical bacillus Calmette–Guérin combined with electromotive mitomycin for high-risk superficial bladder cancer

Nature Clinical Practice Oncology volume 3, pages 474–475 (2006)Cite this article

boxed-textDi Stasi SM et al. (2006) Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. Lancet Oncol 7: 43–51

BCG-based intravesical therapies provide a therapeutic advantage for patients with high-risk, non-muscle-invasive bladder cancer, but diligent long-term follow-up is required

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Holmang S et al. (1995) The relationship among multiple recurrences, progression, and prognosis of patients with stages Ta and T1 transitional cell carcinoma of the bladder followed for at least 20 years. J Urol 153: 18–23

    Article  Google Scholar 

  2. Lundholm C et al. (1996) A randomized prospective study comparing long-term intravesical instillations of mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. J Urol 156: 372–376

    Article  CAS  Google Scholar 

  3. Lamm DL et al. (2000) Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 163: 1124–1129

    Article  CAS  Google Scholar 

  4. Langenstroer P and See W (2000) The role of a second transurethral resection for high grade bladder cancer. Curr Urol Rep 1: 204–207

    Article  CAS  Google Scholar 

  5. Pansadoro V and Emiliozzi P (2006) G3T1 bladder carcinoma. In Textbook of Bladder Cancer, edn 2, 387–396 (Eds Lerner SP et al.) London: Taylor & Francis

    Google Scholar 

  6. Cookson MS et al. (1997) The treated natural history of high risk superficial bladder cancer: 15 year outcome. J Urol 158: 62–67

    Article  CAS  Google Scholar 

  7. Sylvester R et al. (2006) Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49: 466–477

    Article  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Sandra Ford, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. associate attending surgeon in the Department of Urology, Memorial Sloan–Kettering Cancer Center, New York, NY, USA

    Bernard H Bochner

Authors
  1. Bernard H Bochner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bernard H Bochner.

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bochner, B. Intravesical bacillus Calmette–Guérin combined with electromotive mitomycin for high-risk superficial bladder cancer. Nat Rev Clin Oncol 3, 474–475 (2006). https://doi.org/10.1038/ncponc0588

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncponc0588

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing